Joseph Tintelnot

939 total citations
18 papers, 220 citations indexed

About

Joseph Tintelnot is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Joseph Tintelnot has authored 18 papers receiving a total of 220 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 7 papers in Surgery. Recurrent topics in Joseph Tintelnot's work include Gastric Cancer Management and Outcomes (6 papers), Esophageal Cancer Research and Treatment (5 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Joseph Tintelnot is often cited by papers focused on Gastric Cancer Management and Outcomes (6 papers), Esophageal Cancer Research and Treatment (5 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Joseph Tintelnot collaborates with scholars based in Germany, Switzerland and France. Joseph Tintelnot's co-authors include Alexander Stein, Nicola Gagliani, Mascha Binder, Jan Broder Engler, Manuel A. Friese, Christoph Schultheiß, Francesco Siracusa, Carsten Bokemeyer, Friederike Ufer and Filippo Cortesi and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Science Advances.

In The Last Decade

Joseph Tintelnot

18 papers receiving 220 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joseph Tintelnot Germany 9 131 73 58 57 34 18 220
Ann Byrne Australia 6 169 1.3× 71 1.0× 89 1.5× 135 2.4× 46 1.4× 9 316
Ge Qin China 6 146 1.1× 113 1.5× 38 0.7× 98 1.7× 16 0.5× 11 259
Xiaobei Mao China 8 112 0.9× 232 3.2× 29 0.5× 52 0.9× 37 1.1× 12 350
Gaurav Sharma United States 7 91 0.7× 127 1.7× 31 0.5× 35 0.6× 22 0.6× 18 257
Matheus Sewastjanow‐Silva United States 5 68 0.5× 71 1.0× 57 1.0× 18 0.3× 68 2.0× 16 177
Yueyao Yang China 4 144 1.1× 87 1.2× 22 0.4× 134 2.4× 13 0.4× 10 270
Laia Muixí Spain 8 32 0.2× 84 1.2× 23 0.4× 60 1.1× 30 0.9× 11 191
Shu-Jung Hsu China 8 68 0.5× 118 1.6× 64 1.1× 49 0.9× 28 0.8× 13 279
Yinghong Yang China 7 36 0.3× 105 1.4× 88 1.5× 20 0.4× 38 1.1× 24 243
Jessica Yang United States 8 61 0.5× 114 1.6× 24 0.4× 37 0.6× 14 0.4× 20 199

Countries citing papers authored by Joseph Tintelnot

Since Specialization
Citations

This map shows the geographic impact of Joseph Tintelnot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph Tintelnot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph Tintelnot more than expected).

Fields of papers citing papers by Joseph Tintelnot

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph Tintelnot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph Tintelnot. The network helps show where Joseph Tintelnot may publish in the future.

Co-authorship network of co-authors of Joseph Tintelnot

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph Tintelnot. A scholar is included among the top collaborators of Joseph Tintelnot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph Tintelnot. Joseph Tintelnot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Stein, Alexander, Eray Goekkurt, Salah-Eddin Al-Batran, et al.. (2025). Perioperative pembrolizumab, trastuzumab and FLOT in HER2-positive localized esophagogastric adenocarcinoma: a phase 2 trial. Nature Medicine. 31(12). 4197–4204. 1 indexed citations
2.
Well, Lennart, et al.. (2024). Tumor Response Evaluation Using iRECIST: Feasibility and Reliability of Manual Versus Software-Assisted Assessments. Cancers. 16(5). 993–993. 2 indexed citations
3.
Thiele, Benjamin, Alexander Stein, Christoph Schultheiß, et al.. (2024). Trifluridine/Tipiracil Based Chemoradiation in locally Advanced Rectal Cancer: The Phase I/II TARC Trial. Clinical Colorectal Cancer. 24(1). 11–17. 2 indexed citations
4.
Tintelnot, Joseph, et al.. (2024). Roles of microbiota in pancreatic cancer development and treatment. Gut Microbes. 16(1). 2320280–2320280. 27 indexed citations
5.
Woo, Marcel S., Friederike Ufer, Jana K. Sonner, et al.. (2023). Calcium channel β3 subunit regulates ATP-dependent migration of dendritic cells. Science Advances. 9(38). eadh1653–eadh1653. 6 indexed citations
6.
Siracusa, Francesco, Joseph Tintelnot, Filippo Cortesi, & Nicola Gagliani. (2023). Diet and immune response: how today’s plate shapes tomorrow’s health. Trends in Immunology. 45(1). 4–10. 10 indexed citations
7.
Tintelnot, Joseph, Alexander Stein, Salah‐Eddin Al‐Batran, et al.. (2023). Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma—a phase II trial of the AIO study group (AIO STO 0321). Frontiers in Oncology. 13. 1272175–1272175. 3 indexed citations
8.
Nitschke, Christine, Walter Philipp, Anita Badbaran, et al.. (2023). Peripheral and Portal VenousKRASctDNA Detection as Independent Prognostic Markers of Early Tumor Recurrence in Pancreatic Ductal Adenocarcinoma. Clinical Chemistry. 69(3). 295–307. 17 indexed citations
9.
Paschold, Lisa, Alexander Stein, Benjamin Thiele, et al.. (2023). First-line treatment of unresectable or metastatic HER2 positive esophagogastric adenocarcinoma: liquid biomarker analysis of the phase 2 INTEGA trial. Journal for ImmunoTherapy of Cancer. 11(6). e006678–e006678. 8 indexed citations
10.
Tintelnot, Joseph, Alexander Stein, Lisa Paschold, et al.. (2023). Final survival results of ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive esophago gastric adenocarcinoma: The randomized AIO INTEGA trial.. Journal of Clinical Oncology. 41(16_suppl). 4026–4026. 3 indexed citations
11.
Nitschke, Christine, Leonie Konczalla, Yassine Belloum, et al.. (2022). Circulating tumor-macrophage fusion cells as stage independent, unfavourable, prognostic markers in Pancreatic Ductal Adenocarcinoma. European Journal of Surgical Oncology. 48(2). e131–e132. 2 indexed citations
12.
13.
Moehler, Markus, Maurice Stephan Michel, Alexander Stein, et al.. (2021). A Phase I Dose-Escalation Study of Third-Line Regorafenib with Trifluridine/Tipiracil in Metastatic Colorectal Cancer. Future Oncology. 17(25). 3309–3319. 3 indexed citations
14.
15.
Tintelnot, Joseph, Christoph Schultheiß, Friederike Braig, et al.. (2019). Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies. Molecular Cancer Therapeutics. 18(4). 823–833. 26 indexed citations
16.
Tintelnot, Joseph, Friederike Ufer, Jan Broder Engler, et al.. (2019). Arc/Arg3.1 defines dendritic cells and Langerhans cells with superior migratory ability independent of phenotype and ontogeny in mice. European Journal of Immunology. 49(5). 724–736. 3 indexed citations
17.
Tintelnot, Joseph & Alexander Stein. (2019). Immunotherapy in colorectal cancer: Available clinical evidence, challenges and novel approaches. World Journal of Gastroenterology. 25(29). 3920–3928. 43 indexed citations
18.
Ufer, Friederike, Pablo Vargas, Jan Broder Engler, et al.. (2016). Arc/Arg3.1 governs inflammatory dendritic cell migration from the skin and thereby controls T cell activation. Science Immunology. 1(3). eaaf8665–eaaf8665. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ann Byrne Breakdown of academic impact, for papers by Ge Qin Breakdown of academic impact, for papers by Xiaobei Mao Breakdown of academic impact, for papers by Gaurav Sharma Breakdown of academic impact, for papers by Matheus Sewastjanow‐Silva Breakdown of academic impact, for papers by Yueyao Yang Breakdown of academic impact, for papers by Laia Muixí Breakdown of academic impact, for papers by Shu-Jung Hsu Breakdown of academic impact, for papers by Yinghong Yang Breakdown of academic impact, for papers by Jessica Yang
Rankless by CCL
2026